Analysis of Profitability Ratios
Quarterly Data
Profitability ratios measure the company’s ability to generate profitable sales from its resources (assets).
Profitability Ratios (Summary)
Johnson & Johnson, profitability ratios (quarterly data)
Based on: 10-Q (filing date: 2020-10-23), 10-Q (filing date: 2020-07-24), 10-Q (filing date: 2020-04-29), 10-K (filing date: 2020-02-18), 10-Q (filing date: 2019-10-28), 10-Q (filing date: 2019-07-29), 10-Q (filing date: 2019-05-01), 10-K (filing date: 2019-02-20), 10-Q (filing date: 2018-10-31), 10-Q (filing date: 2018-08-02), 10-Q (filing date: 2018-05-01), 10-K (filing date: 2018-02-21), 10-Q (filing date: 2017-11-02), 10-Q (filing date: 2017-08-03), 10-Q (filing date: 2017-05-08), 10-K (filing date: 2017-02-27), 10-Q (filing date: 2016-11-04), 10-Q (filing date: 2016-08-04), 10-Q (filing date: 2016-05-10), 10-K (filing date: 2016-02-24), 10-Q (filing date: 2015-10-30), 10-Q (filing date: 2015-07-31), 10-Q (filing date: 2015-05-01).
| Profitability ratio | Description | The company |
|---|---|---|
| Gross profit margin | Gross profit margin indicates the percentage of revenue available to cover operating and other expenditures. | Johnson & Johnson’s gross profit margin ratio deteriorated from Q1 2020 to Q2 2020 but then slightly improved from Q2 2020 to Q3 2020. |
| Operating profit margin | A profitability ratio calculated as operating income divided by revenue. | Johnson & Johnson’s operating profit margin ratio deteriorated from Q1 2020 to Q2 2020 and from Q2 2020 to Q3 2020. |
| Net profit margin | An indicator of profitability, calculated as net income divided by revenue. | Johnson & Johnson’s net profit margin ratio deteriorated from Q1 2020 to Q2 2020 but then improved from Q2 2020 to Q3 2020 exceeding Q1 2020 level. |
| Profitability ratio | Description | The company |
|---|---|---|
| ROE | A profitability ratio calculated as net income divided by shareholders’ equity. | Johnson & Johnson’s ROE deteriorated from Q1 2020 to Q2 2020 but then improved from Q2 2020 to Q3 2020 not reaching Q1 2020 level. |
| ROA | A profitability ratio calculated as net income divided by total assets. | Johnson & Johnson’s ROA deteriorated from Q1 2020 to Q2 2020 but then slightly improved from Q2 2020 to Q3 2020. |
Gross Profit Margin
Johnson & Johnson, gross profit margin calculation (quarterly data)
| Sep 27, 2020 | Jun 28, 2020 | Mar 29, 2020 | Dec 29, 2019 | Sep 29, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 30, 2018 | Sep 30, 2018 | Jul 1, 2018 | Apr 1, 2018 | Dec 31, 2017 | Oct 1, 2017 | Jul 2, 2017 | Apr 2, 2017 | Dec 31, 2016 | Oct 2, 2016 | Jul 3, 2016 | Apr 3, 2016 | Dec 31, 2015 | Sep 27, 2015 | Jun 28, 2015 | Mar 29, 2015 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||||||
| Gross profit | 14,110 | 11,757 | 13,629 | 13,613 | 13,862 | 13,622 | 13,406 | 13,433 | 13,759 | 13,903 | 13,395 | 12,952 | 12,748 | 13,016 | 12,380 | 12,572 | 12,334 | 13,146 | 12,153 | 12,138 | 11,878 | 12,430 | 12,092 | |||||||
| Sales to customers | 21,082 | 18,336 | 20,691 | 20,747 | 20,729 | 20,562 | 20,021 | 20,394 | 20,348 | 20,830 | 20,009 | 20,195 | 19,650 | 18,839 | 17,766 | 18,106 | 17,820 | 18,482 | 17,482 | 17,811 | 17,102 | 17,787 | 17,374 | |||||||
| Profitability Ratio | ||||||||||||||||||||||||||||||
| Gross profit margin1 | 65.68% | 65.66% | 66.15% | 66.42% | 66.49% | 66.67% | 66.80% | 66.79% | 66.36% | 65.69% | 66.22% | 66.84% | 68.20% | 69.35% | 69.88% | 69.84% | 69.52% | 69.58% | 69.25% | 69.27% | — | — | — | |||||||
| Benchmarks | ||||||||||||||||||||||||||||||
| Gross Profit Margin, Competitors2 | ||||||||||||||||||||||||||||||
| Abbott Laboratories | 50.18% | 50.97% | 52.13% | 52.46% | 52.39% | 52.17% | 51.57% | 51.32% | 50.57% | 50.38% | 49.39% | 47.75% | 48.59% | 49.21% | 51.32% | 54.09% | 54.17% | 53.99% | 53.93% | 54.19% | — | — | — | |||||||
| AbbVie Inc. | 68.74% | 73.56% | 77.43% | 77.64% | 77.32% | 77.41% | 77.07% | 76.44% | 75.22% | 74.93% | 75.18% | 75.05% | 76.85% | 76.78% | 76.81% | 77.25% | 77.21% | 78.12% | 79.28% | 80.31% | — | — | — | |||||||
| Amgen Inc. | 75.55% | 77.15% | 78.90% | 80.38% | 81.19% | 81.23% | 81.26% | 81.80% | 81.61% | 81.78% | 81.69% | 81.33% | 81.37% | 81.26% | 81.05% | 80.99% | 80.68% | 80.64% | 80.23% | 79.82% | — | — | — | |||||||
| Biogen Inc. | 87.65% | 87.97% | 87.47% | 86.40% | 85.97% | 85.59% | 85.72% | 86.50% | 86.12% | 86.43% | 86.57% | 86.72% | 87.34% | 86.80% | 86.56% | 87.08% | 87.46% | 88.21% | 88.65% | 88.48% | — | — | — | |||||||
| Bristol-Myers Squibb Co. | 71.18% | 69.47% | 68.02% | 69.10% | 69.90% | 70.10% | 70.86% | 70.98% | 70.37% | 70.12% | 69.62% | 70.80% | 71.92% | 72.78% | 74.19% | 74.54% | 75.56% | 75.55% | 75.67% | 76.39% | — | — | — | |||||||
| Eli Lilly & Co. | 78.26% | 78.67% | 79.22% | 78.85% | 77.78% | 76.67% | 74.96% | 73.81% | 73.39% | 72.92% | 72.95% | 73.46% | 73.69% | 73.89% | 73.78% | 73.35% | 73.23% | 73.72% | 74.39% | 74.76% | — | — | — | |||||||
| Gilead Sciences Inc. | 78.72% | 78.25% | 79.06% | 78.86% | 79.27% | 78.98% | 78.02% | 77.61% | 79.21% | 80.31% | 81.82% | 82.97% | 84.51% | 84.71% | 85.95% | 85.77% | 86.36% | 86.91% | 86.69% | 87.54% | — | — | — | |||||||
| Illumina Inc. | 69.02% | 70.34% | 70.36% | 69.63% | 69.24% | 68.84% | 69.06% | 69.01% | 69.44% | 68.85% | 67.98% | 66.35% | 65.68% | 66.26% | 67.53% | 69.48% | 69.91% | 69.96% | 69.74% | 69.80% | — | — | — | |||||||
| Merck & Co. Inc. | 71.23% | 70.06% | 70.11% | 69.87% | 70.13% | 69.89% | 68.94% | 68.06% | 67.35% | 67.81% | 68.22% | 68.16% | 68.09% | 67.92% | 66.61% | 65.10% | 63.89% | 62.58% | 62.07% | 62.19% | — | — | — | |||||||
| Pfizer Inc. | 79.86% | 79.94% | 79.94% | 80.25% | 79.85% | 79.91% | 79.36% | 79.03% | 78.58% | 78.24% | 78.48% | 78.61% | 78.66% | 78.15% | 77.28% | 76.66% | 76.48% | 77.71% | 79.09% | 80.25% | — | — | — | |||||||
| Regeneron Pharmaceuticals Inc. | 87.98% | 88.21% | 89.72% | 90.05% | 91.14% | 92.27% | 92.79% | 93.53% | 93.36% | 93.28% | 92.95% | 93.24% | 93.37% | 94.16% | 94.53% | 93.83% | 92.90% | 91.38% | 90.52% | 90.43% | — | — | — | |||||||
| Vertex Pharmaceuticals Inc. | 88.01% | 87.71% | 87.24% | 86.84% | 86.60% | 86.56% | 86.74% | 86.56% | 86.88% | 87.31% | 87.59% | 88.95% | 89.04% | 89.08% | 89.76% | 87.64% | 87.16% | 87.72% | 87.39% | 87.94% | — | — | — | |||||||
| Zoetis Inc. | 69.64% | 69.73% | 69.51% | 68.18% | 67.38% | 66.92% | 66.49% | 67.19% | 68.12% | 68.04% | 67.31% | 66.55% | 65.14% | 64.91% | 65.30% | 65.92% | 65.32% | 64.90% | 64.08% | 63.53% | — | — | — | |||||||
Based on: 10-Q (filing date: 2020-10-23), 10-Q (filing date: 2020-07-24), 10-Q (filing date: 2020-04-29), 10-K (filing date: 2020-02-18), 10-Q (filing date: 2019-10-28), 10-Q (filing date: 2019-07-29), 10-Q (filing date: 2019-05-01), 10-K (filing date: 2019-02-20), 10-Q (filing date: 2018-10-31), 10-Q (filing date: 2018-08-02), 10-Q (filing date: 2018-05-01), 10-K (filing date: 2018-02-21), 10-Q (filing date: 2017-11-02), 10-Q (filing date: 2017-08-03), 10-Q (filing date: 2017-05-08), 10-K (filing date: 2017-02-27), 10-Q (filing date: 2016-11-04), 10-Q (filing date: 2016-08-04), 10-Q (filing date: 2016-05-10), 10-K (filing date: 2016-02-24), 10-Q (filing date: 2015-10-30), 10-Q (filing date: 2015-07-31), 10-Q (filing date: 2015-05-01).
1 Q3 2020 Calculation
Gross profit margin = 100
× (Gross profitQ3 2020
+ Gross profitQ2 2020
+ Gross profitQ1 2020
+ Gross profitQ4 2019)
÷ (Sales to customersQ3 2020
+ Sales to customersQ2 2020
+ Sales to customersQ1 2020
+ Sales to customersQ4 2019)
= 100 × (14,110 + 11,757 + 13,629 + 13,613)
÷ (21,082 + 18,336 + 20,691 + 20,747)
= 65.68%
2 Click competitor name to see calculations.
| Profitability ratio | Description | The company |
|---|---|---|
| Gross profit margin | Gross profit margin indicates the percentage of revenue available to cover operating and other expenditures. | Johnson & Johnson’s gross profit margin ratio deteriorated from Q1 2020 to Q2 2020 but then slightly improved from Q2 2020 to Q3 2020. |
Operating Profit Margin
Johnson & Johnson, operating profit margin calculation (quarterly data)
| Sep 27, 2020 | Jun 28, 2020 | Mar 29, 2020 | Dec 29, 2019 | Sep 29, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 30, 2018 | Sep 30, 2018 | Jul 1, 2018 | Apr 1, 2018 | Dec 31, 2017 | Oct 1, 2017 | Jul 2, 2017 | Apr 2, 2017 | Dec 31, 2016 | Oct 2, 2016 | Jul 3, 2016 | Apr 3, 2016 | Dec 31, 2015 | Sep 27, 2015 | Jun 28, 2015 | Mar 29, 2015 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||||||
| Operating earnings | 5,633 | 3,990 | 5,788 | 4,238 | 5,820 | 5,353 | 4,403 | 4,154 | 4,494 | 5,464 | 5,686 | 2,740 | 4,709 | 5,458 | 5,498 | 4,428 | 5,322 | 5,563 | 5,332 | 2,660 | 4,633 | 4,917 | 5,346 | |||||||
| Sales to customers | 21,082 | 18,336 | 20,691 | 20,747 | 20,729 | 20,562 | 20,021 | 20,394 | 20,348 | 20,830 | 20,009 | 20,195 | 19,650 | 18,839 | 17,766 | 18,106 | 17,820 | 18,482 | 17,482 | 17,811 | 17,102 | 17,787 | 17,374 | |||||||
| Profitability Ratio | ||||||||||||||||||||||||||||||
| Operating profit margin1 | 24.30% | 24.64% | 25.62% | 24.15% | 24.15% | 22.63% | 22.69% | 24.27% | 22.59% | 23.05% | 23.63% | 24.07% | 27.02% | 28.55% | 28.83% | 28.72% | 26.37% | 25.66% | 25.00% | 25.05% | — | — | — | |||||||
| Benchmarks | ||||||||||||||||||||||||||||||
| Operating Profit Margin, Competitors2 | ||||||||||||||||||||||||||||||
| Abbott Laboratories | 13.39% | 12.78% | 14.18% | 14.21% | 13.74% | 13.27% | 12.31% | 11.94% | 10.45% | 10.11% | 8.92% | 6.30% | 7.89% | 8.77% | 11.03% | 15.27% | 14.74% | 13.95% | 13.64% | 14.05% | — | — | — | |||||||
| AbbVie Inc. | 28.45% | 30.17% | 39.86% | 39.03% | 20.04% | 21.85% | 19.88% | 19.49% | 32.99% | 32.84% | 34.03% | 33.99% | 37.24% | 36.74% | 36.33% | 36.60% | 36.21% | 35.00% | 34.18% | 32.97% | — | — | — | |||||||
| Amgen Inc. | 38.59% | 39.76% | 41.89% | 43.57% | 44.83% | 44.05% | 44.53% | 45.55% | 45.82% | 46.46% | 46.07% | 45.76% | 46.66% | 46.93% | 45.68% | 44.74% | 43.33% | 42.46% | 41.53% | 40.44% | — | — | — | |||||||
| Biogen Inc. | 46.68% | 50.93% | 51.03% | 48.98% | 47.13% | 46.90% | 42.40% | 43.77% | 44.67% | 45.58% | 46.49% | 43.54% | 40.25% | 38.72% | 41.59% | 44.99% | 47.59% | 47.86% | 47.11% | 45.44% | — | — | — | |||||||
| Bristol-Myers Squibb Co. | 9.27% | 11.67% | 16.30% | 22.62% | 28.63% | 28.59% | 23.43% | 22.69% | 18.64% | 15.93% | 17.50% | 17.39% | 19.71% | 21.73% | 24.06% | 23.83% | 19.21% | 16.34% | 11.09% | 11.41% | — | — | — | |||||||
| Eli Lilly & Co. | 23.55% | 24.48% | 25.64% | 22.29% | 20.00% | 19.48% | 12.50% | 15.15% | 12.34% | 9.11% | 14.88% | 9.38% | 12.43% | 14.23% | 12.92% | 16.30% | 14.31% | 14.56% | 14.27% | 13.47% | — | — | — | |||||||
| Gilead Sciences Inc. | 11.01% | -4.40% | 19.89% | 19.38% | 19.71% | 38.44% | 37.87% | 37.83% | 42.81% | 46.25% | 51.51% | 55.04% | 58.72% | 58.71% | 58.46% | 58.87% | 61.67% | 63.83% | 66.22% | 69.03% | — | — | — | |||||||
| Illumina Inc. | 22.08% | 25.69% | 27.28% | 27.80% | 26.42% | 24.88% | 25.58% | 26.49% | 28.25% | 27.58% | 26.29% | 22.02% | 20.01% | 20.06% | 21.35% | 24.48% | 24.80% | 24.55% | 24.77% | 27.61% | — | — | — | |||||||
| Merck & Co. Inc. | 26.87% | 25.40% | 25.49% | 24.77% | 25.56% | 26.73% | 24.38% | 19.62% | 17.84% | 12.28% | 13.57% | 16.28% | 9.92% | 16.85% | 14.45% | 13.51% | 19.60% | 18.10% | 18.19% | 17.54% | — | — | — | |||||||
| Pfizer Inc. | 24.77% | 23.75% | 25.38% | 25.46% | 26.30% | 27.50% | 26.86% | 26.10% | 26.18% | 26.00% | 25.86% | 25.92% | 24.69% | 23.57% | 22.94% | 22.73% | 22.96% | 24.02% | 24.86% | 24.20% | — | — | — | |||||||
| Regeneron Pharmaceuticals Inc. | 37.43% | 34.64% | 30.45% | 28.10% | 29.55% | 29.58% | 35.41% | 37.77% | 37.00% | 36.89% | 36.54% | 35.41% | 34.22% | 32.29% | 28.76% | 27.38% | 25.67% | 26.77% | 29.26% | 30.51% | — | — | — | |||||||
| Vertex Pharmaceuticals Inc. | 44.43% | 38.67% | 34.05% | 28.77% | 21.38% | 25.48% | 23.98% | 20.84% | 22.38% | 3.87% | -0.77% | 4.95% | 1.62% | 16.16% | 14.62% | 0.58% | -5.02% | -8.65% | -23.94% | -45.23% | — | — | — | |||||||
| Zoetis Inc. | 33.87% | 33.36% | 32.72% | 31.42% | 31.01% | 29.80% | 30.05% | 31.12% | 33.00% | 33.86% | 33.02% | 32.15% | 29.43% | 28.34% | 28.55% | 28.48% | 26.22% | 24.91% | 17.35% | 15.74% | — | — | — | |||||||
Based on: 10-Q (filing date: 2020-10-23), 10-Q (filing date: 2020-07-24), 10-Q (filing date: 2020-04-29), 10-K (filing date: 2020-02-18), 10-Q (filing date: 2019-10-28), 10-Q (filing date: 2019-07-29), 10-Q (filing date: 2019-05-01), 10-K (filing date: 2019-02-20), 10-Q (filing date: 2018-10-31), 10-Q (filing date: 2018-08-02), 10-Q (filing date: 2018-05-01), 10-K (filing date: 2018-02-21), 10-Q (filing date: 2017-11-02), 10-Q (filing date: 2017-08-03), 10-Q (filing date: 2017-05-08), 10-K (filing date: 2017-02-27), 10-Q (filing date: 2016-11-04), 10-Q (filing date: 2016-08-04), 10-Q (filing date: 2016-05-10), 10-K (filing date: 2016-02-24), 10-Q (filing date: 2015-10-30), 10-Q (filing date: 2015-07-31), 10-Q (filing date: 2015-05-01).
1 Q3 2020 Calculation
Operating profit margin = 100
× (Operating earningsQ3 2020
+ Operating earningsQ2 2020
+ Operating earningsQ1 2020
+ Operating earningsQ4 2019)
÷ (Sales to customersQ3 2020
+ Sales to customersQ2 2020
+ Sales to customersQ1 2020
+ Sales to customersQ4 2019)
= 100 × (5,633 + 3,990 + 5,788 + 4,238)
÷ (21,082 + 18,336 + 20,691 + 20,747)
= 24.30%
2 Click competitor name to see calculations.
| Profitability ratio | Description | The company |
|---|---|---|
| Operating profit margin | A profitability ratio calculated as operating income divided by revenue. | Johnson & Johnson’s operating profit margin ratio deteriorated from Q1 2020 to Q2 2020 and from Q2 2020 to Q3 2020. |
Net Profit Margin
Johnson & Johnson, net profit margin calculation (quarterly data)
| Sep 27, 2020 | Jun 28, 2020 | Mar 29, 2020 | Dec 29, 2019 | Sep 29, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 30, 2018 | Sep 30, 2018 | Jul 1, 2018 | Apr 1, 2018 | Dec 31, 2017 | Oct 1, 2017 | Jul 2, 2017 | Apr 2, 2017 | Dec 31, 2016 | Oct 2, 2016 | Jul 3, 2016 | Apr 3, 2016 | Dec 31, 2015 | Sep 27, 2015 | Jun 28, 2015 | Mar 29, 2015 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||||||
| Net earnings | 3,554 | 3,626 | 5,796 | 4,010 | 1,753 | 5,607 | 3,749 | 3,042 | 3,934 | 3,954 | 4,367 | (10,713) | 3,764 | 3,827 | 4,422 | 3,814 | 4,272 | 3,997 | 4,457 | 3,215 | 3,358 | 4,516 | 4,320 | |||||||
| Sales to customers | 21,082 | 18,336 | 20,691 | 20,747 | 20,729 | 20,562 | 20,021 | 20,394 | 20,348 | 20,830 | 20,009 | 20,195 | 19,650 | 18,839 | 17,766 | 18,106 | 17,820 | 18,482 | 17,482 | 17,811 | 17,102 | 17,787 | 17,374 | |||||||
| Profitability Ratio | ||||||||||||||||||||||||||||||
| Net profit margin1 | 21.01% | 18.86% | 20.75% | 18.42% | 17.32% | 20.08% | 17.99% | 18.75% | 1.89% | 1.70% | 1.58% | 1.70% | 21.28% | 22.52% | 22.87% | 23.01% | 22.27% | 21.20% | 22.15% | 21.99% | — | — | — | |||||||
| Benchmarks | ||||||||||||||||||||||||||||||
| Net Profit Margin, Competitors2 | ||||||||||||||||||||||||||||||
| Abbott Laboratories | 10.50% | 9.89% | 11.15% | 11.56% | 10.50% | 9.36% | 8.53% | 7.74% | 2.91% | 3.13% | 1.67% | 1.74% | 8.37% | 4.96% | 6.74% | 6.71% | 6.61% | 11.08% | 12.00% | 21.68% | — | — | — | |||||||
| AbbVie Inc. | 18.16% | 19.20% | 24.77% | 23.69% | 9.90% | 12.62% | 16.42% | 17.36% | 23.50% | 20.84% | 21.55% | 18.82% | 24.38% | 24.77% | 24.07% | 23.22% | 24.08% | 23.11% | 23.03% | 22.50% | — | — | — | |||||||
| Amgen Inc. | 30.91% | 31.53% | 33.64% | 35.32% | 36.14% | 35.57% | 35.93% | 37.25% | 9.96% | 10.72% | 10.11% | 9.08% | 37.36% | 37.24% | 36.12% | 35.27% | 35.19% | 34.48% | 33.86% | 33.13% | — | — | — | |||||||
| Biogen Inc. | 35.63% | 40.91% | 40.76% | 40.96% | 37.91% | 37.62% | 33.79% | 32.93% | 24.08% | 23.06% | 23.54% | 20.69% | 29.44% | 28.10% | 30.17% | 32.34% | 34.03% | 33.97% | 33.79% | 32.95% | — | — | — | |||||||
| Bristol-Myers Squibb Co. | -0.11% | -1.61% | 3.08% | 13.15% | 23.39% | 26.00% | 22.09% | 21.81% | 6.50% | 1.74% | 4.37% | 4.85% | 20.56% | 22.66% | 24.22% | 22.94% | 18.22% | 16.29% | 9.31% | 9.45% | — | — | — | |||||||
| Eli Lilly & Co. | 24.01% | 24.48% | 23.97% | 37.27% | 35.10% | 33.76% | 26.12% | 13.16% | 1.85% | -0.60% | 4.82% | -0.89% | 9.90% | 11.12% | 10.13% | 12.90% | 11.73% | 11.97% | 11.49% | 12.07% | — | — | — | |||||||
| Gilead Sciences Inc. | 5.56% | -1.18% | 22.17% | 24.35% | 12.24% | 27.14% | 26.93% | 25.16% | 7.27% | 9.69% | 14.26% | 18.03% | 42.90% | 43.55% | 44.11% | 45.07% | 48.40% | 51.16% | 53.48% | 56.32% | — | — | — | |||||||
| Illumina Inc. | 19.70% | 20.68% | 26.49% | 28.28% | 28.13% | 27.55% | 25.05% | 24.78% | 21.09% | 20.88% | 19.31% | 26.38% | 30.14% | 30.07% | 30.52% | 19.29% | 18.70% | 18.70% | 18.40% | 20.79% | — | — | — | |||||||
| Merck & Co. Inc. | 24.33% | 22.20% | 21.10% | 21.01% | 20.26% | 21.10% | 19.50% | 14.71% | 8.02% | 3.25% | 3.88% | 5.97% | 7.15% | 12.71% | 10.88% | 9.85% | 13.76% | 13.01% | 11.72% | 11.25% | — | — | — | |||||||
| Pfizer Inc. | 17.85% | 28.80% | 31.17% | 31.45% | 30.57% | 23.58% | 21.31% | 20.79% | 44.63% | 42.35% | 41.29% | 40.55% | 18.69% | 15.90% | 13.88% | 13.66% | 11.77% | 13.47% | 14.95% | 14.25% | — | — | — | |||||||
| Regeneron Pharmaceuticals Inc. | 38.28% | 37.30% | 28.56% | 26.91% | 28.13% | 28.59% | 35.12% | 36.42% | 28.24% | 25.65% | 23.54% | 20.41% | 23.17% | 22.05% | 19.34% | 18.42% | 16.85% | 15.98% | 16.72% | 15.50% | — | — | — | |||||||
| Vertex Pharmaceuticals Inc. | 44.91% | 38.51% | 31.35% | 28.27% | 59.23% | 64.13% | 66.01% | 68.80% | 22.87% | 15.84% | 9.36% | 10.59% | 8.53% | 12.19% | 8.78% | -6.58% | -13.17% | -17.66% | -30.91% | -53.89% | — | — | — | |||||||
| Zoetis Inc. | 25.42% | 25.50% | 25.41% | 23.96% | 23.76% | 22.74% | 23.47% | 24.52% | 20.35% | 19.95% | 17.97% | 16.28% | 18.29% | 17.50% | 17.25% | 16.80% | 14.10% | 13.15% | 7.83% | 7.11% | — | — | — | |||||||
Based on: 10-Q (filing date: 2020-10-23), 10-Q (filing date: 2020-07-24), 10-Q (filing date: 2020-04-29), 10-K (filing date: 2020-02-18), 10-Q (filing date: 2019-10-28), 10-Q (filing date: 2019-07-29), 10-Q (filing date: 2019-05-01), 10-K (filing date: 2019-02-20), 10-Q (filing date: 2018-10-31), 10-Q (filing date: 2018-08-02), 10-Q (filing date: 2018-05-01), 10-K (filing date: 2018-02-21), 10-Q (filing date: 2017-11-02), 10-Q (filing date: 2017-08-03), 10-Q (filing date: 2017-05-08), 10-K (filing date: 2017-02-27), 10-Q (filing date: 2016-11-04), 10-Q (filing date: 2016-08-04), 10-Q (filing date: 2016-05-10), 10-K (filing date: 2016-02-24), 10-Q (filing date: 2015-10-30), 10-Q (filing date: 2015-07-31), 10-Q (filing date: 2015-05-01).
1 Q3 2020 Calculation
Net profit margin = 100
× (Net earningsQ3 2020
+ Net earningsQ2 2020
+ Net earningsQ1 2020
+ Net earningsQ4 2019)
÷ (Sales to customersQ3 2020
+ Sales to customersQ2 2020
+ Sales to customersQ1 2020
+ Sales to customersQ4 2019)
= 100 × (3,554 + 3,626 + 5,796 + 4,010)
÷ (21,082 + 18,336 + 20,691 + 20,747)
= 21.01%
2 Click competitor name to see calculations.
| Profitability ratio | Description | The company |
|---|---|---|
| Net profit margin | An indicator of profitability, calculated as net income divided by revenue. | Johnson & Johnson’s net profit margin ratio deteriorated from Q1 2020 to Q2 2020 but then improved from Q2 2020 to Q3 2020 exceeding Q1 2020 level. |
Return on Equity (ROE)
Johnson & Johnson, ROE calculation (quarterly data)
| Sep 27, 2020 | Jun 28, 2020 | Mar 29, 2020 | Dec 29, 2019 | Sep 29, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 30, 2018 | Sep 30, 2018 | Jul 1, 2018 | Apr 1, 2018 | Dec 31, 2017 | Oct 1, 2017 | Jul 2, 2017 | Apr 2, 2017 | Dec 31, 2016 | Oct 2, 2016 | Jul 3, 2016 | Apr 3, 2016 | Dec 31, 2015 | Sep 27, 2015 | Jun 28, 2015 | Mar 29, 2015 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||||||
| Net earnings | 3,554 | 3,626 | 5,796 | 4,010 | 1,753 | 5,607 | 3,749 | 3,042 | 3,934 | 3,954 | 4,367 | (10,713) | 3,764 | 3,827 | 4,422 | 3,814 | 4,272 | 3,997 | 4,457 | 3,215 | 3,358 | 4,516 | 4,320 | |||||||
| Shareholders’ equity | 64,473 | 62,978 | 61,294 | 59,471 | 58,210 | 60,785 | 58,955 | 59,752 | 64,626 | 62,889 | 63,255 | 60,160 | 73,979 | 71,922 | 70,341 | 70,418 | 72,769 | 72,473 | 72,647 | 71,150 | 71,554 | 71,131 | 67,878 | |||||||
| Profitability Ratio | ||||||||||||||||||||||||||||||
| ROE1 | 26.35% | 24.11% | 28.01% | 25.42% | 24.31% | 26.87% | 24.90% | 25.60% | 2.39% | 2.18% | 1.97% | 2.16% | 21.39% | 22.71% | 23.46% | 23.49% | 21.91% | 20.73% | 21.40% | 21.66% | — | — | — | |||||||
| Benchmarks | ||||||||||||||||||||||||||||||
| ROE, Competitors2 | ||||||||||||||||||||||||||||||
| Abbott Laboratories | 10.78% | 10.17% | 11.84% | 11.86% | 10.35% | 9.14% | 8.48% | 7.76% | 2.89% | 3.03% | 1.52% | 1.54% | 6.57% | 3.71% | 4.79% | 6.82% | 6.59% | 11.02% | 11.81% | 20.85% | — | — | — | |||||||
| AbbVie Inc. | 48.34% | 47.30% | — | — | — | — | — | — | — | — | 179.59% | 104.16% | 99.42% | 110.08% | 126.25% | 128.41% | 93.97% | 101.42% | 117.94% | 130.39% | — | — | — | |||||||
| Amgen Inc. | 67.09% | 68.48% | 80.92% | 81.07% | 73.83% | 73.73% | 74.55% | 67.15% | 15.35% | 15.86% | 14.21% | 7.84% | 25.37% | 25.77% | 25.76% | 25.85% | 24.65% | 24.67% | 25.16% | 24.71% | — | — | — | |||||||
| Biogen Inc. | 47.24% | 52.41% | 46.85% | 44.13% | 38.55% | 40.87% | 33.74% | 33.98% | 23.15% | 24.21% | 21.09% | 20.13% | 27.10% | 28.42% | 30.31% | 30.50% | 32.06% | 33.48% | 35.78% | 37.84% | — | — | — | |||||||
| Bristol-Myers Squibb Co. | -0.09% | -1.15% | 1.91% | 6.66% | 32.04% | 38.65% | 33.80% | 35.07% | 10.50% | 3.05% | 7.18% | 8.58% | 28.61% | 31.20% | 33.55% | 27.55% | 21.56% | 19.24% | 10.94% | 10.97% | — | — | — | |||||||
| Eli Lilly & Co. | 115.45% | 137.26% | 179.72% | 319.09% | 234.97% | 282.08% | 252.24% | 32.88% | 3.44% | -1.24% | 7.74% | -1.76% | 14.94% | 17.35% | 15.58% | 19.54% | 15.68% | 16.85% | 15.45% | 16.53% | — | — | — | |||||||
| Gilead Sciences Inc. | 7.27% | -1.43% | 22.49% | 23.91% | 13.07% | 26.33% | 26.84% | 25.51% | 6.94% | 10.19% | 16.82% | 22.64% | 46.69% | 53.86% | 61.82% | 71.48% | 89.38% | 105.21% | 129.43% | 97.70% | — | — | — | |||||||
| Illumina Inc. | 13.57% | 15.19% | 20.32% | 21.72% | 21.92% | 21.65% | 21.36% | 21.98% | 19.53% | 19.90% | 18.85% | 26.41% | 27.38% | 27.54% | 29.01% | 21.06% | 19.79% | 21.05% | 20.82% | 24.97% | — | — | — | |||||||
| Merck & Co. Inc. | 39.47% | 37.91% | 38.72% | 37.99% | 34.70% | 33.88% | 30.50% | 23.30% | 10.32% | 4.12% | 4.69% | 6.97% | 7.44% | 12.89% | 10.91% | 9.78% | 12.55% | 11.84% | 10.53% | 9.94% | — | — | — | |||||||
| Pfizer Inc. | 13.31% | 22.02% | 24.28% | 25.77% | 24.91% | 21.24% | 19.52% | 17.59% | 33.40% | 32.31% | 29.72% | 29.88% | 16.14% | 14.26% | 12.49% | 12.12% | 9.90% | 11.22% | 12.09% | 10.75% | — | — | — | |||||||
| Regeneron Pharmaceuticals Inc. | 31.17% | 32.94% | 18.79% | 19.08% | 20.41% | 21.21% | 25.70% | 27.91% | 22.85% | 22.14% | 21.74% | 19.51% | 21.12% | 20.91% | 19.79% | 20.13% | 17.75% | 18.23% | 19.69% | 17.40% | — | — | — | |||||||
| Vertex Pharmaceuticals Inc. | 33.08% | 27.67% | 23.38% | 19.34% | 40.81% | 43.70% | 45.63% | 47.28% | 22.27% | 15.46% | 9.41% | 12.99% | 10.93% | 15.55% | 11.82% | -9.69% | -21.41% | -28.03% | -41.73% | -59.19% | — | — | — | |||||||
| Zoetis Inc. | 46.17% | 54.23% | 58.52% | 55.39% | 54.56% | 57.03% | 59.91% | 65.35% | 54.96% | 56.60% | 49.90% | 48.81% | 47.11% | 51.20% | 53.14% | 55.21% | 43.47% | 47.09% | 32.45% | 31.74% | — | — | — | |||||||
Based on: 10-Q (filing date: 2020-10-23), 10-Q (filing date: 2020-07-24), 10-Q (filing date: 2020-04-29), 10-K (filing date: 2020-02-18), 10-Q (filing date: 2019-10-28), 10-Q (filing date: 2019-07-29), 10-Q (filing date: 2019-05-01), 10-K (filing date: 2019-02-20), 10-Q (filing date: 2018-10-31), 10-Q (filing date: 2018-08-02), 10-Q (filing date: 2018-05-01), 10-K (filing date: 2018-02-21), 10-Q (filing date: 2017-11-02), 10-Q (filing date: 2017-08-03), 10-Q (filing date: 2017-05-08), 10-K (filing date: 2017-02-27), 10-Q (filing date: 2016-11-04), 10-Q (filing date: 2016-08-04), 10-Q (filing date: 2016-05-10), 10-K (filing date: 2016-02-24), 10-Q (filing date: 2015-10-30), 10-Q (filing date: 2015-07-31), 10-Q (filing date: 2015-05-01).
1 Q3 2020 Calculation
ROE = 100
× (Net earningsQ3 2020
+ Net earningsQ2 2020
+ Net earningsQ1 2020
+ Net earningsQ4 2019)
÷ Shareholders’ equity
= 100 × (3,554 + 3,626 + 5,796 + 4,010)
÷ 64,473 = 26.35%
2 Click competitor name to see calculations.
| Profitability ratio | Description | The company |
|---|---|---|
| ROE | A profitability ratio calculated as net income divided by shareholders’ equity. | Johnson & Johnson’s ROE deteriorated from Q1 2020 to Q2 2020 but then improved from Q2 2020 to Q3 2020 not reaching Q1 2020 level. |
Return on Assets (ROA)
Johnson & Johnson, ROA calculation (quarterly data)
| Sep 27, 2020 | Jun 28, 2020 | Mar 29, 2020 | Dec 29, 2019 | Sep 29, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 30, 2018 | Sep 30, 2018 | Jul 1, 2018 | Apr 1, 2018 | Dec 31, 2017 | Oct 1, 2017 | Jul 2, 2017 | Apr 2, 2017 | Dec 31, 2016 | Oct 2, 2016 | Jul 3, 2016 | Apr 3, 2016 | Dec 31, 2015 | Sep 27, 2015 | Jun 28, 2015 | Mar 29, 2015 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||||||
| Net earnings | 3,554 | 3,626 | 5,796 | 4,010 | 1,753 | 5,607 | 3,749 | 3,042 | 3,934 | 3,954 | 4,367 | (10,713) | 3,764 | 3,827 | 4,422 | 3,814 | 4,272 | 3,997 | 4,457 | 3,215 | 3,358 | 4,516 | 4,320 | |||||||
| Total assets | 170,693 | 158,380 | 155,017 | 157,728 | 155,521 | 155,117 | 150,027 | 152,954 | 155,703 | 155,365 | 156,625 | 157,303 | 155,658 | 152,807 | 144,918 | 141,208 | 140,369 | 139,814 | 136,231 | 133,411 | 133,266 | 132,036 | 128,590 | |||||||
| Profitability Ratio | ||||||||||||||||||||||||||||||
| ROA1 | 9.95% | 9.59% | 11.07% | 9.59% | 9.10% | 10.53% | 9.78% | 10.00% | 0.99% | 0.88% | 0.79% | 0.83% | 10.17% | 10.69% | 11.39% | 11.71% | 11.36% | 10.75% | 11.41% | 11.55% | — | — | — | |||||||
| Benchmarks | ||||||||||||||||||||||||||||||
| ROA, Competitors2 | ||||||||||||||||||||||||||||||
| Abbott Laboratories | 4.90% | 4.52% | 5.36% | 5.43% | 4.80% | 4.23% | 3.88% | 3.53% | 1.24% | 1.35% | 0.67% | 0.63% | 2.91% | 1.65% | 2.12% | 2.66% | 3.47% | 5.72% | 6.17% | 10.72% | — | — | — | |||||||
| AbbVie Inc. | 4.93% | 4.65% | 9.25% | 8.84% | 5.48% | 7.21% | 9.44% | 9.58% | 11.43% | 10.46% | 9.20% | 7.50% | 9.66% | 9.87% | 9.61% | 9.01% | 9.12% | 8.51% | 10.19% | 9.70% | — | — | — | |||||||
| Amgen Inc. | 11.37% | 11.23% | 12.45% | 13.13% | 13.55% | 13.40% | 12.62% | 12.64% | 3.27% | 3.49% | 3.12% | 2.48% | 10.18% | 10.27% | 10.14% | 9.95% | 9.71% | 9.85% | 9.61% | 9.69% | — | — | — | |||||||
| Biogen Inc. | 20.38% | 23.23% | 22.51% | 21.62% | 19.63% | 20.14% | 17.65% | 17.52% | 12.50% | 12.39% | 11.36% | 10.73% | 15.11% | 15.13% | 16.42% | 16.19% | 17.58% | 17.75% | 17.87% | 18.19% | — | — | — | |||||||
| Bristol-Myers Squibb Co. | -0.04% | -0.44% | 0.74% | 2.65% | 9.85% | 11.24% | 14.77% | 14.06% | 4.24% | 1.15% | 2.78% | 3.00% | 12.45% | 13.73% | 14.68% | 13.22% | 9.98% | 8.74% | 4.94% | 4.93% | — | — | — | |||||||
| Eli Lilly & Co. | 12.68% | 13.39% | 13.46% | 21.17% | 20.97% | 20.28% | 16.46% | 7.36% | 1.01% | -0.34% | 2.53% | -0.45% | 5.17% | 5.98% | 5.81% | 7.05% | 6.50% | 6.76% | 6.68% | 6.77% | — | — | — | |||||||
| Gilead Sciences Inc. | 2.08% | -0.46% | 8.31% | 8.74% | 4.55% | 9.42% | 9.38% | 8.57% | 2.47% | 3.38% | 5.30% | 6.58% | 17.94% | 20.27% | 21.90% | 23.70% | 26.63% | 32.71% | 36.30% | 34.93% | — | — | — | |||||||
| Illumina Inc. | 8.62% | 9.56% | 12.97% | 13.70% | 13.73% | 13.45% | 11.52% | 11.87% | 10.12% | 11.08% | 10.23% | 13.81% | 15.49% | 15.39% | 16.10% | 10.81% | 10.49% | 10.86% | 10.93% | 12.52% | — | — | — | |||||||
| Merck & Co. Inc. | 12.83% | 11.56% | 11.95% | 11.66% | 11.18% | 11.15% | 10.20% | 7.53% | 3.93% | 1.58% | 1.84% | 2.72% | 3.11% | 5.48% | 4.50% | 4.11% | 5.58% | 5.32% | 4.67% | 4.36% | — | — | — | |||||||
| Pfizer Inc. | 4.85% | 7.96% | 9.49% | 9.72% | 9.51% | 8.10% | 7.38% | 7.00% | 14.19% | 13.67% | 13.21% | 12.40% | 5.70% | 4.94% | 4.32% | 4.20% | 3.51% | 4.13% | 4.68% | 4.16% | — | — | — | |||||||
| Regeneron Pharmaceuticals Inc. | 19.62% | 20.68% | 14.46% | 14.29% | 15.38% | 15.71% | 18.88% | 20.83% | 16.64% | 15.99% | 15.23% | 13.67% | 14.69% | 14.24% | 12.32% | 12.84% | 11.68% | 11.97% | 12.56% | 11.34% | — | — | — | |||||||
| Vertex Pharmaceuticals Inc. | 23.81% | 20.37% | 16.99% | 14.15% | 28.53% | 31.50% | 32.94% | 33.57% | 14.00% | 9.58% | 5.72% | 7.43% | 6.12% | 7.91% | 6.02% | -3.87% | -8.38% | -10.79% | -16.05% | -22.26% | — | — | — | |||||||
| Zoetis Inc. | 12.12% | 12.37% | 13.97% | 12.99% | 12.96% | 12.52% | 12.75% | 13.25% | 11.13% | 12.96% | 11.25% | 10.06% | 10.09% | 11.25% | 11.18% | 10.73% | 8.93% | 8.50% | 5.07% | 4.28% | — | — | — | |||||||
Based on: 10-Q (filing date: 2020-10-23), 10-Q (filing date: 2020-07-24), 10-Q (filing date: 2020-04-29), 10-K (filing date: 2020-02-18), 10-Q (filing date: 2019-10-28), 10-Q (filing date: 2019-07-29), 10-Q (filing date: 2019-05-01), 10-K (filing date: 2019-02-20), 10-Q (filing date: 2018-10-31), 10-Q (filing date: 2018-08-02), 10-Q (filing date: 2018-05-01), 10-K (filing date: 2018-02-21), 10-Q (filing date: 2017-11-02), 10-Q (filing date: 2017-08-03), 10-Q (filing date: 2017-05-08), 10-K (filing date: 2017-02-27), 10-Q (filing date: 2016-11-04), 10-Q (filing date: 2016-08-04), 10-Q (filing date: 2016-05-10), 10-K (filing date: 2016-02-24), 10-Q (filing date: 2015-10-30), 10-Q (filing date: 2015-07-31), 10-Q (filing date: 2015-05-01).
1 Q3 2020 Calculation
ROA = 100
× (Net earningsQ3 2020
+ Net earningsQ2 2020
+ Net earningsQ1 2020
+ Net earningsQ4 2019)
÷ Total assets
= 100 × (3,554 + 3,626 + 5,796 + 4,010)
÷ 170,693 = 9.95%
2 Click competitor name to see calculations.
| Profitability ratio | Description | The company |
|---|---|---|
| ROA | A profitability ratio calculated as net income divided by total assets. | Johnson & Johnson’s ROA deteriorated from Q1 2020 to Q2 2020 but then slightly improved from Q2 2020 to Q3 2020. |